Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02538029 · ClinicalTrials.gov registry record · NA
The Effects of Dual Task Training in Individuals With Parkinson's Disease
A NA study of Parkinson's Disease, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT02538029: Completed NA study of Parkinson's Disease, sponsored by The Cleveland Clinic.
NCT02538029 is a NA study of Parkinson's Disease that has completed, run by The Cleveland Clinic. The registered enrollment target is 45 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02538029, a NA study of Parkinson's Disease, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of the proposed project is to characterize dual tasking (DT) deficits to improve motor, cognitive, and quality of life outcomes in individuals with Parkinson's disease (PD). Phase 1 of the intervention will involve an in-depth gait analysis on 15 individuals with PD. This gait analysis will utilize the Computer Assisted Rehabilitation Environment (CAREN) system, a virtual reality system with a fully integrated 3-D motion capture system. The purpose of Phase 1 is to generalize characteristics of gait and postural control during specific DT conditions. Phase 2 (N=20) involves the clinical translation of these findings. This phase will involve creating a clinical intervention based on the objective information gathered the CAREN system. The intervention will take place 3x/week for a total of 8 weeks. Interventional groups will include: 1) DT clinical group (N=10) and 2) Single task group (N=10). Outcome measures will be used at the beginning and end of the intervention to assess the feasibility and efficacy of the intervention.
Primary Outcome
The average distance from heel strike of the less affected leg to heel strike of the more affected leg. Higher values indicate a longer step length.
Conditions Studied
Interventions
- BEHAVIORAL Dual Task Group
- BEHAVIORAL Single Task Group
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-08-16 |
| Phase | NA |
What the finished NCT02538029 record still lists
NCT02538029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Dual Task Group is the first listed.
NCT02538029 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02538029 about?
NCT02538029 is a clinical study titled "The Effects of Dual Task Training in Individuals With Parkinson's Disease". The primary aim of the proposed project is to characterize dual tasking (DT) deficits to improve motor, cognitive, and quality of life outcomes in individuals with Parkinson's disease (PD). Phase 1 of the intervention will involve an in-depth gait analysis on 15 individuals with PD. This gait analys...
What is the current status of trial NCT02538029?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2015-08. Estimated completion is 2017-08-16.
What conditions does trial NCT02538029 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT02538029?
The interventions under investigation include: Dual Task Group (BEHAVIORAL), Single Task Group (BEHAVIORAL).
Who is sponsoring clinical trial NCT02538029?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02538029 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02538029's enrollment target sits among peer trials
45 90th of 158 higher than 69 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease
RECRUITING · NA
-
Effects of Pallidal Deep Brain Stimulation Location on Motor Impairment in Parkinson's Disease
RECRUITING · NA
-
Remote Dynamic Cycling for the Customized Off-site Rehab in Parkinson's Disease
RECRUITING · NA
-
Deep Brain Stimulation Therapy in Movement Disorders
RECRUITING · NA
-
Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia